Company · TEM
Healthcare · 1 research article
Delayed up to 15 min · Source: Finnhub · Not investment advice
Tempus grew revenue 23% and adjusted EBITDA to $25.6M, but a $42.8M unrealized gain materially improved the GAAP loss while operating cash remained negative.
| Company | View | Revenue YoY | EPS YoY | Guidance | Last report | |
|---|---|---|---|---|---|---|
| TEM diagnostics | LONG | — | — | — | — | |
| ABBV AbbVie | LONG | +10.3% | — | raised | Oct 30, 2026 | Compare |
| ABT comparable sales growth | LONG | +14.5% | — | maintained | Oct 21, 2026 | Compare |
| BMY Bristol-Myers Squibb | LONG | +7% | — | raised | Oct 29, 2026 | Compare |
| CVS CVS Health | LONG | +7.3% | — | raised | Aug 5, 2026 | Compare |
| DHR Danaher | LONG | +8.5% | — | revised | Oct 21, 2026 | Compare |
| GEHC organic revenue | LONG | — | — | — | — | Compare |
| HUM Humana | LONG | — | — | — | — | Compare |
Growth figures are year-over-year changes extracted automatically from each company's latest earnings release and can contain errors.
Widgets by TradingView. They load only when you click, so the page stays fast.
Forensic equity research on US stocks. No spam, unsubscribe anytime.
